PR
TNGX icon

PSP Research’s Tango Therapeutics TNGX Stock Holding History

PSP Research’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$313K Sell
10,000
-4,400
-31% -$109K 0.17% 47
2026
Q1 		$301K Buy
+14,400
New +$200K 0.21% 59

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

PSP Research's TNGX Position: Q2 2026 in Review

PSP Research reduced its Tango Therapeutics (TNGX) stake by 31% in Q2 2026, selling an estimated $109K and leaving 10,000 shares worth $313K. The position accounts for 0.17% of the portfolio, ranked #47.

PSP Research first reported a position in TNGX in Q1 2026 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • PSP Research held 10,000 shares of Tango Therapeutics worth $313K as of Q2 2026.
  • PSP Research sold 4,400 Tango Therapeutics shares in Q2 2026, an estimated $109K.
  • Tango Therapeutics made up 0.17% of PSP Research's portfolio in Q2 2026, its #47 holding.
  • PSP Research first reported a position in Tango Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.